Biotech Small-Cap Approvals β May 14, 2026
This week's seven FDA approvals in the Biotech Small-Cap stream comprise 1 NME (PEGFILGRASTIM-PCCG by ACCORD BIOPHARMA INC.), 5 biosimilars (LEVETIRACETAM by MYLAN LABS LTD, HYDROCORTISONE SODIUM SUCCINATE by ZYDUS PHARMS, PALIPERIDONE by I3 PHARMS, BRIMONIDINE TARTRATE by MICRO LABS, Unknown by DR REDDYS LABS LTD), and 1 label expansion (DOLUTEGRAVIR by LACHMAN CONSULTANT SERVICES, INC.), overriding the aggregate '7 Other' mix with detailed classifications. No dominant therapeutic area theme, as approvals span neurology/psychiatry (LEVETIRACETAM, PALIPERIDONE), ophthalmology (BRIMONIDINE TARTRATE), HIV (DOLUTEGRAVIR), and oncology supportive care (PEGFILGRASTIM-PCCG). Highest-conviction signal is ACCORD BIOPHARMA INC.'s NME approval for PEGFILGRASTIM-PCCG (ENNUMO), a bullish catalyst with 8/10 strength and materiality, signaling 5-year NCE exclusivity and strong execution for this small-cap entrant. Overall, 2 bullish signals dominate amid 5 neutrals, favoring selective small-cap upside. Key risk/watch item: Biosimilar entries intensify competitive pressure and potential 30-60% revenue erosion for originators over 2-3 years, though originators unnamed.